Voxelotor tablets bulk supplier for pharma manufacturers

Voxelotor Tablets 500 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 500 mg

Reference Brands: Oxbryta(US)

Voxelotor inhibits hemoglobin S polymerization by binding to hemoglobin, increasing its oxygen affinity. This reduces sickling of red blood cells, decreasing hemolysis and improving anemia. Benefits include raising hemoglobin levels, reducing sickle cell crises, and enhancing quality of life for patients with sickle cell disease.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Voxelotor, marketed as Oxbryta, is approved in the US by the FDA for treating sickle cell disease. In the EU, regulatory approval is pending or under review. Approval requires a comprehensive dossier including clinical trial data, safety, efficacy, pharmacovigilance, and manufacturing details. In the US, submission involves detailed clinical study review, while the EU follows EMA guidelines for authorization. For guidance on dossier preparation, regulatory pathways, and successful market entry strategies, visit PharmaTradz. Ensuring compliance with regional regulations is essential for the safe, approved, and effective use of voxelotor worldwide, supporting patients with sickle cell disease.

Voxelotor Tablets — third party manufacturing & bulk supply

Voxelotor Tablets 500 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Voxelotor Tablets is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Voxelotor Tablets listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Voxelotor Tablets →

Back to Listing

Frequently Asked Questions

Voxelotor tablets is listed as Tablet in 500 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Voxelotor tablets is referenced against Oxbryta(US). Reference brands are shown for identification only and remain the property of their respective trademark owners.